Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25386279 | 1.00 | ALDH1A1 (0.39) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL25386278 | 1.00 | ALDH1A1 (0.39) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL30149256 | 1.00 | ALDH1A1 (0.39) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL28934101 | 0.88 | TRPA1 (0.32) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL28934100 | 0.88 | TRPA1 (0.32) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL29668584 | 0.88 | TRPA1 (0.32) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL28934099 | 0.88 | TRPA1 (0.32) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL30951871 | 0.73 | ALDH1A1 (0.44) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL29261125 | 0.73 | ALDH1A1 (0.44) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL29261124 | 0.73 | ALDH1A1 (0.44) | ALDH1A1KDM4EGLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| CN-115461334-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4242202-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GLP1R, GIPR, GCGR | ALDH1A1 1985/4885KDM4E 3725/4885GLA 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.